{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T09:24:13Z","timestamp":1795166653634,"version":"4.10.3"},"reference-count":38,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"unspecified","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Barlow Family Glaucoma Fund","award":["RKL\u2019s research supported by Barlow Family Glaucoma"],"award-info":[{"award-number":["RKL\u2019s research supported by Barlow Family Glaucoma"]}]},{"name":"Camiener Foundation Glaucoma Research Fund","award":["RKL\u2019s research supported by Camiener Foundation"],"award-info":[{"award-number":["RKL\u2019s research supported by Camiener Foundation"]}]},{"name":"Gutierrez Family Research Fund","award":["RKL\u2019s research is supported by Gutierrez Family Re"],"award-info":[{"award-number":["RKL\u2019s research is supported by Gutierrez Family Re"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2026,4,26]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Systemic antihypertensive medications may influence glaucoma-related outcomes through intraocular pressure\u2013dependent and vascular mechanisms. While topical \u03b1\u2082-agonists are established glaucoma therapies, the association between systemic \u03b1\u2082-agonists and glaucoma hazard remains unexamined; we compared their hazard with systemic \u03b2-blockers in adults with hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We conducted a multicentre retrospective cohort study using deidentified electronic health records. Adults aged \u226540 years with hypertension and chronic exposure to systemic \u03b1\u2082-agonists or \u03b2-blockers were included. Patients with pre-existing ocular hypertension (OHT), primary open-angle glaucoma (POAG), concomitant comparator use, or inadequate ophthalmic follow-up were excluded. We balanced cohorts using propensity score matching (PSM) and assessed the hazard of OHT and POAG at 1, 3, and 5 years. Cox models estimated adjusted HRs (aHRs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients treated with \u03b1\u2082-agonists (n=4186) were matched to those treated with \u03b2-blockers (n=360\u2009399), resulting in 4152 patients per group after PSM. In Cox models (on the unmatched cohorts) adjusted for demographics, comorbidities, medications, laboratory and biometric measures, socioeconomic indicators and selected procedures, \u03b1\u2082-agonist exposure was associated with a lower hazard of OHT (aHR (95%\u2009CI) 0.582 (0.473 to 0.716), 0.559 (0.468 to 0.669) and 0.534 (0.450 to 0.634)) and POAG (aHR (95%\u2009CI) 0.359 (0.300 to 0.429), 0.333 (0.282 to 0.392) and 0.334 (0.286 to 0.390)) at 1-year, 3-year, and 5-year follow-up, respectively (all p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Systemic \u03b1\u2082-agonist use was associated with a substantially lower hazard of glaucoma-related diagnoses compared with systemic \u03b2-blocker use. These findings are limited by the observational design, potential residual confounding, and reliance on diagnostic coding. These results warrant further investigation in prospective mechanistic studies and randomised clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2026-002760","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:40:18Z","timestamp":1778168418000},"page":"e002760","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic \u03b1\u2082-agonist use and lower hazard of glaucoma compared with \u03b2-blockers: a cohort study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7014-1760","authenticated-orcid":false,"given":"Ibrahim","family":"Abboud","sequence":"first","affiliation":[{"name":"University of California Riverside School of Medicine, Riverside, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin Z","family":"Khudari","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-5970","authenticated-orcid":false,"given":"Abdelaziz","family":"Abdelaal","sequence":"additional","affiliation":[{"name":"Tanta University, Tanta, Gharbia Governorate, Egypt"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Almobayed","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhi J","family":"Al\u2019Aref","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S","family":"Myers","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-375X","authenticated-orcid":false,"given":"Abdelrahman M","family":"Elhusseiny","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA"},{"name":"Department of Ophthalmology, Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"},{"name":"Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026090204201503000_11.2.e002760.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"2026090204201503000_11.2.e002760.2","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1177\/11206721251340435","article-title":"Medical and surgical treatment management in open angle glaucoma patients of Asian descent: A narrative review","volume":"35","author":"Belamkar","year":"2025","journal-title":"Eur J Ophthalmol"},{"key":"2026090204201503000_11.2.e002760.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.029"},{"key":"2026090204201503000_11.2.e002760.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192"},{"key":"2026090204201503000_11.2.e002760.5","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100020100038"},{"key":"2026090204201503000_11.2.e002760.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.07.051"},{"key":"2026090204201503000_11.2.e002760.7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ajo.2024.12.024","article-title":"GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis","volume":"271","author":"Amaral","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"2026090204201503000_11.2.e002760.8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2025.07.014","article-title":"Association Between Chronic Oral Nitrate Use and the Risk of Ocular Hypertension and Open-Angle Glaucoma","volume":"279","author":"Elhusseiny","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"2026090204201503000_11.2.e002760.9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ajo.2025.04.003","article-title":"Racial and Ethnic Differences in the Association Between Statin Use and the Risk of Ocular Hypertension and Open-Angle Glaucoma","volume":"276","author":"Elhusseiny","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"2026090204201503000_11.2.e002760.10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.749858","article-title":"Topical Medication Therapy for Glaucoma and Ocular Hypertension","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026090204201503000_11.2.e002760.11","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ophtha.2014.04.016","article-title":"Nocturnal systemic hypotension increases the risk of glaucoma progression","volume":"121","author":"Charlson","year":"2014","journal-title":"Ophthalmology"},{"key":"2026090204201503000_11.2.e002760.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.017"},{"key":"2026090204201503000_11.2.e002760.13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2023.03.014","article-title":"A Systematic Review and Meta-analysis of Systemic Antihypertensive Medications With Intraocular Pressure and Glaucoma","volume":"255","author":"Leung","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"2026090204201503000_11.2.e002760.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43420-3","article-title":"Effect of antihypertensive medications on the risk of open-angle glaucoma","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep"},{"key":"2026090204201503000_11.2.e002760.15","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0039-6257(96)82027-3","article-title":"Preclinical evaluation of brimonidine","volume":"41 Suppl 1","author":"Burke","year":"1996","journal-title":"Surv Ophthalmol"},{"key":"2026090204201503000_11.2.e002760.16","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.797"},{"key":"2026090204201503000_11.2.e002760.17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1017\/S0952523807070605","article-title":"Localization of alpha 2 receptors in ocular tissues","volume":"24","author":"Woldemussie","year":"2007","journal-title":"Vis Neurosci"},{"key":"2026090204201503000_11.2.e002760.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2011.04.002"},{"key":"2026090204201503000_11.2.e002760.19","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1177\/112067210101102S03","article-title":"Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma","volume":"11 Suppl 2","author":"Wheeler","year":"2001","journal-title":"Eur J Ophthalmol"},{"key":"2026090204201503000_11.2.e002760.20","doi-asserted-by":"crossref","unstructured":"MACMAHON B , WEISS NS , POCOCK SJ , et al . The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Strobe Initiative 2007;18. doi:10.1097\/EDE.0b013e3181577654","DOI":"10.1097\/EDE.0b013e3181577654"},{"key":"2026090204201503000_11.2.e002760.21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ophtha.2023.05.001","article-title":"Association of Systemic Medication Use with Glaucoma and Intraocular Pressure: The European Eye Epidemiology Consortium","volume":"130","author":"Vergroesen","year":"2023","journal-title":"Ophthalmology"},{"key":"2026090204201503000_11.2.e002760.22","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.131"},{"key":"2026090204201503000_11.2.e002760.23","first-page":"2299","article-title":"Characterization of alpha2 adrenergic receptor subtypes in human ocular tissue homogenates","volume":"40","author":"Bylund","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026090204201503000_11.2.e002760.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.09.026"},{"key":"2026090204201503000_11.2.e002760.25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0161-6420(13)31818-1","article-title":"Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study","volume":"100","author":"Nagasubramanian","year":"1993","journal-title":"Ophthalmology"},{"key":"2026090204201503000_11.2.e002760.26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.anclin.2017.01.009","article-title":"Alpha-2 Agonists","volume":"35","author":"Nguyen","year":"2017","journal-title":"Anesthesiol Clin"},{"key":"2026090204201503000_11.2.e002760.27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0259-1162.156312","article-title":"Efficacy of alpha2 agonists in obtunding rise in intraocular pressure after succinylcholine and that following laryngoscopy and intubation","volume":"9","author":"Rajan","year":"2015","journal-title":"Anesth Essays Res"},{"key":"2026090204201503000_11.2.e002760.28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/eye.1989.71","article-title":"Review of alpha adrenoceptor function in the eye","volume":"3 (Pt 4)","author":"McAuliffe-Curtin","year":"1989","journal-title":"Eye (Lond)"},{"key":"2026090204201503000_11.2.e002760.29","doi-asserted-by":"publisher","DOI":"10.1007\/s13167-018-0155-5"},{"key":"2026090204201503000_11.2.e002760.30","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1016\/j.survophthal.2007.08.010","article-title":"What is the link between vascular dysregulation and glaucoma?","volume":"52 Suppl 2","author":"Grieshaber","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"2026090204201503000_11.2.e002760.31","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.65.14.4","article-title":"Change in Systemic Medication and its Influence on Intraocular Pressure - Results From the Gutenberg Health Study","volume":"65","author":"Laspas","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026090204201503000_11.2.e002760.32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41433-019-0603-z","article-title":"A review of systemic medications that may modulate the risk of glaucoma","volume":"34","author":"Wu","year":"2020","journal-title":"Eye (Lond)"},{"key":"2026090204201503000_11.2.e002760.33","first-page":"2267","article-title":"Association of commonly used systemic medications with glaucoma prevalence and intraocular pressure across Europe: the E3 Consortium","volume":"63","author":"Schuster","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026090204201503000_11.2.e002760.34","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.8.856"},{"key":"2026090204201503000_11.2.e002760.35","doi-asserted-by":"publisher","DOI":"10.1345\/aph.18464"},{"key":"2026090204201503000_11.2.e002760.36","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200104000-00009"},{"key":"2026090204201503000_11.2.e002760.37","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/IJG.0000000000001315","article-title":"Use of Topical Intraocular Pressure-lowering Medications in the US Population: Results From the NHANES Study 1999 to 2014","volume":"28","author":"Lowry","year":"2019","journal-title":"J Glaucoma"},{"key":"2026090204201503000_11.2.e002760.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.optom.2016.02.003"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2026-002760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:20:28Z","timestamp":1788348028000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2026-002760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,7]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjophth-2026-002760"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2026-002760","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}